Kellie Rohwer, APRN
Adult Health · Oklahoma City, OKNPI 1033530266
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 501 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AstraZeneca$1K
- GSK$702
- Insmed, Inc.$678
- Regeneron Healthcare Solutions, Inc.$674
- Boehringer Ingelheim$646
- plus $5K from 30 others
What the payments were for
- Food & beverage$9,80393%
- Education$7097%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 56 | $1,292 |
| AstraZeneca(2 entities) | 38 | $1,242 |
| GSK | 55 | $702 |
| Insmed, Inc. | 30 | $678 |
| Regeneron Healthcare Solutions, Inc. | 33 | $674 |
| Boehringer Ingelheim | 26 | $646 |
| Jazz Pharmaceuticals Inc. | 17 | $601 |
| Baxter Healthcare | 22 | $517 |
| Inspire Medical Systems, Inc. | 16 | $398 |
| Axsome Therapeutics, Inc. | 22 | $378 |
| Harmony Biosciences LLC | 18 | $340 |
| Actelion Pharmaceuticals US, Inc. | 7 | $307 |
| Inogen, Inc. | 27 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $247 |
| Mylan Specialty L.p. | 21 | $237 |
| Merck | 9 | $196 |
| Amgen | 11 | $186 |
| Sanofi-aventis U.S. LLC | 3 | $178 |
| Electromed, Inc. | 9 | $178 |
| Verona Pharma, Inc. | 14 | $174 |
| United Therapeutics Corporation | 7 | $161 |
| Viatris Specialty LLC | 15 | $153 |
| ANI Pharmaceuticals, Inc. | 7 | $138 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $135 |
| Lilly USA, LLC | 4 | $89 |
| AbbVie | 3 | $84 |
| Novartis | 2 | $53 |
| Esperion Therapeutics, Inc. | 1 | $45 |
| Pulmonx Corporation | 2 | $40 |
| Masimo Corporation | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $14 |
| 3b Medical, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,512 in reported general payments places this provider in the 95th percentile of 117 adult health providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 292 | $235,103 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $66,634 |
| Spiriva RespimatTiotropium Bromide | 46 | $30,438 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $27,474 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $11,156 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $10,723 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $7,996 |
| DuleraMometasone/Formoterol | 20 | $5,959 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 182 | $4,132 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,384 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $2,906 |
| Montelukast Sodium | 93 | $1,316 |
| Azelastine Hcl | 34 | $880 |
| Roflumilast | 15 | $873 |
| Fluticasone Propionate | 29 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $702 | $262,577340 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,242 | $77,790129 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $646 | $41,16167 claims |
| MerckDulera | $196 | $5,95920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 adult health providers in Oklahoma.
Other adult health in Oklahoma City
- Cynthia CattaneoOklahoma City$45K
- Miki ThompsonOklahoma City$14K
- Terry GreenOklahoma City$9K
- Nissy PhilipOklahoma City$8K
- Alexis StinnettOklahoma City$6K
- Michael EskewOklahoma City$5K
- Candace BeckerOklahoma City$5K
- Anna CottleOklahoma City$5K
- Tyler AgeeOklahoma City$4K
- Kristen SweetOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.